Bio-Gene Technology Ltd
BGT
Company Profile
Business description
Bio-Gene Technology Ltd is to pursue the development and commercialisation of naturally derived insecticide products. Its insecticide active ingredients are Flavocide, a synthetically produced nature-identical compound, and Qcide, a natural plant-derived oil with high levels of tasmanone. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Contact
400 Collins Street
Level 6
MelbourneVIC3000
AUST: +61 390681062
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,980.15 | 10.15 | 0.13% |
| DAX 40 | 25,858.16 | 181.52 | -0.70% |
| Dow JONES (US) | 52,168.09 | 174.47 | -0.33% |
| FTSE 100 | 10,723.43 | 1.36 | 0.01% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,628.52 | 91.87 | -1.19% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |